Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425723 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
A Phase 3 study, sponsored by Bioverativ Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT01425723 is a Phase 3 study that has completed, run by Bioverativ Therapeutics. The registered enrollment target is 120 participants.
The verdict
NCT01425723, a Phase 3 study, has completed, sponsored by Bioverativ Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the long-term safety of rFIXFc in participants with hemophilia B. The secondary objective of this study is to evaluate the efficacy of rFIXFc in the prevention and treatment of bleeding episodes.
Interventions
- BIOLOGICAL rFIXFc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-12-08 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01425723
The ClinicalTrials.gov registry entry for NCT01425723 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bioverativ Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rFIXFc is the first listed.
NCT01425723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01425723 about?
NCT01425723 is a clinical study titled "Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B". The primary objective of the study is to evaluate the long-term safety of rFIXFc in participants with hemophilia B. The secondary objective of this study is to evaluate the efficacy of rFIXFc in the prevention and treatment of bleeding episodes.
What is the current status of trial NCT01425723?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2011-12-08. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01425723?
The interventions under investigation include: rFIXFc (BIOLOGICAL).
Who is sponsoring clinical trial NCT01425723?
This trial is sponsored by Bioverativ Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.